The DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index.
Gut Microbiota–Related Biomarkers in Immuno-Oncology
Open accessAbstract
Carcinogenesis is associated with the emergence of protracted intestinal dysbiosis and metabolic changes. Increasing evidence shows that gut microbiota-related biomarkers and microbiota-centered interventions are promising strategies to overcome resistance to immunotherapy. However, current standard methods for evaluating gut microbiota composition are cost- and time-consuming. The development of routine diagnostic tools for intestinal barrier alterations and dysbiosis constitutes a critical unmet medical need that can guide routine treatment and microbiota-centered intervention decisions in patients with cancer. In this review, we explore the influence of gut microbiota on cancer immunotherapy and highlight gut-associated biomarkers that have the potential to be transformed into simple diagnostic tools, thus guiding standard treatment decisions in the field of immuno-oncology. Mechanistic insights toward leveraging the complex relationship between cancer immunosurveillance, gut microbiota, and metabolism open exciting opportunities for developing novel biomarkers in immuno-oncology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients with CRC commonly show elevated serum pro-inflammatory cytokines (such as tumor necrosis factor-α (TNF-α) and IL-6) and C-reactive protein alongside high LBP.87”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [87]
In the citing paper
“Other systemic indicators of epithelial injury include intestinal fatty acid-binding protein, which reflects enterocyte damage, and circulating citrulline, a marker of functional mucosal surface area.87”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [87]
In the citing paper
“The foundation guild typically contains butyrate-producing and mucosa-protective taxa such as Faecalibacterium spp., Akkermansia spp., and members of the Lachnospiraceae and Oscillospiraceae families.87,146,182,185”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [87]
In the citing paper
“Antibiotics and PPIs are well recognized for disrupting gut microbial balance (Silva et al., 2025), with antibiotics in particular often leading to dysbiosis.”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Silva et al., 2025
In the citing paper
“Likewise, an accumulation of immunosuppressive secondary bile acids (e.g., lithocholic or deoxycholic acid) or shifts in trimethylamine N-oxide can signal a microbiome tipping into an unbalanced state—often accompanied by compromised inflammatory control and tumor responsiveness (Silva et al., 2025; Thomas et al., 2023; Varanasi et al., 2025).”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Silva et al., 2025
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
1 retracted
RETRACTED ARTICLE: Antibodies against endogenous retroviruses promote lung cancer immunotherapy
Ng, K. W., Boumelha, J., Enfield, K. S. S., Almagro, J., Cha, H., Pich, O., Karasaki, T., Moore, D. A., Salgado, R., Sivakumar, M., et al. (2023) · Nature · doi:10.1038/s41586-023-05771-9 · Cited by 248
RetractedKEGG: Kyoto Encyclopedia of Genes and Genomes
Kanehisa, M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.27 · Cited by 37,077
Hallmarks of Cancer: New Dimensions
Hanahan, D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1059 · Cited by 9,887
From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites
Koh, A., De Vadder, F., Kovatcheva-Datchary, P., & Bäckhed, F. (2016) · Cell · doi:10.1016/j.cell.2016.05.041 · Cited by 7,070
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Self-citationRevised Estimates for the Number of Human and Bacteria Cells in the Body
Sender, R., Fuchs, S., & Milo, R. (2016) · PLOS Biology · doi:10.1371/journal.pbio.1002533 · Cited by 5,425
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Self-citationRichness of human gut microbiome correlates with metabolic markers
Le Chatelier, E., Nielsen, T., Qin, J., Prifti, E., Hildebrand, F., Falony, G., Almeida, M., Arumugam, M., Batto, J.-M., Kennedy, S., et al. (2013) · Nature · doi:10.1038/nature12506 · Cited by 4,662
Research works printed but not linked: 4
- 2022, Longitudinal analysis reveals gut microbiota shift during standard therapies in metastatic renal cell carcinoma (mRCC), Ann. Oncol., 33, 1452MO
- 2016, Biomarkers of gut barrier failure in the ICU, Curr. Opin. Crit. Care, 22, 152
- 2023, Association of circulating markers of gut barrier damage and inflammation with colorectal neoplasia stage, Cancer Res, 83, 5544
- 2013, METABOLOMICSSTANDARD—Metabolomics: defining the standards for sample preparation of small molecules
Cited by
Huang, M., Ji, Q., Huang, H., Wang, X., & Wang, L. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2486519 · Cited by 57
Gut dysbiosis in oncology: a risk factor for immunoresistance
(2026) · doi:10.1038/s41422-025-01212-6 · Cited by 24
Self-citationWekking, D., Silva, C. A. C., Viscò, R., Denaro, N., Lambertini, M., Maccioni, A., Loddo, E., Willard-Gallo, K. E., Scartozzi, M., Derosa, L., et al. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104767 · Cited by 30
Self-citationContext-dependent impact of type I interferon signaling in cancer
Ruiz-Iglesias, A., Guilbaud, E., Galluzzi, L., & Mañes, S. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02495-4 · Cited by 27
Surrogate markers of intestinal dysfunction associated with survival in advanced cancers
Birebent, R., Drubay, D., Alves Costa Silva, C., Marmorino, F., Vitali, G., Piccinno, G., Hurtado, Y., Bonato, A., Belluomini, L., Messaoudene, M., et al. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2484880 · Cited by 21
Self-citation
Metadata
- Authors
- Silva, C. A. C., Fidelle, M., Almonte, A. A., Derosa, L., & Zitvogel, L.
- Affiliations
- Inserm (FR)
- Venue
- Annual Review of Pharmacology and Toxicology
- Publisher
- Annual Reviews
- Published
- 2025-01-23
- Volume
- 65
- Issue
- 1
- Pages
- 333-354
- ISSN
- 0362-1642 (ISSN-L)
- 1545-4304
- OpenAlex
- W4402432767
- Cited by
- 22
- References
- 137
- Citations by year
- 2026: 10 · 2025: 11
- FWCI
- 0.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- The Annual Review of Pharmacology and Toxicology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- theses.fr (ABES) (submittedVersion, other-oa)
- HAL (submittedVersion, other-oa)
- Funders
- Agence Nationale de la Recherche (ANR-21-RHUS-0017, ANR-18-IDEX-0001)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- gut microbiota, biomarkers, cancer immunotherapy, immunotherapy resistance, gut dysbiosis, intestinal barrier, tumor surveillance, cancer metabolism, diagnostic tools, carcinogenesis
- MeSH terms
- Gastrointestinal Microbiome, Animals, Humans, Immunotherapy, Neoplasms, Biomarkers, Tumor, Biomarkers, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gut Microbiota–Related Biomarkers in Immuno-Oncology. https://app.cochat.ai/papers/10.1146/annurev-pharmtox-061124-102218
- The paper
- Silva, C. A. C., Fidelle, M., Almonte, A. A., Derosa, L., & Zitvogel, L. (2025). Gut Microbiota–Related Biomarkers in Immuno-Oncology. Annual Review of Pharmacology and Toxicology. https://doi.org/10.1146/annurev-pharmtox-061124-102218
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.